contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


promising-results-farons-bexmab-blood-cancer-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Someone is providing the funding, that much is already clear. As for who, we’ll just have to wait and see. Could it be BP, the one most interested in Faron…

This is what I already tried to ask on 27.1.26, but since you guys don’t answer correctly   Inderes also reports that MEDSIR is funding, but it’s not clear from that either. There’s nothing else for it but to ask in the next webcast if necessary or then

Sure, sure. If phase 2 is implemented here, the rights to the data will certainly have a hefty price. Especially if high-quality data suitable for applications is produced. So there are no free lunches on offer, as one might infer from the message. Faron will likely provide information on the details of this collaboration once the deal is finalized.

Could Medsir still get money from treating patients? I mean, if it’s a for-profit company?

Why would Medsir fund research without any revenue?

If any future potential returns from Bex, such as royalties, were to be shared with MEDSIR or others through agreements, it would likely have to be announced via a stock exchange release. No such release has been issued, so that is not the case. Release 2.3.26: ”Bexmarilimab is Faron’s wholly owned, investigational immunotherapy”. And if we were already in the royalty phase for solid tumors, it would mean royalties from big pharma. They might not like it during contract negotiations if the rights were already scattered globally. If a randomized Phase 2 BEXAR trial of that scale—278 patients—were conducted as a multicenter study in Europe instead of at a single site, it could, with good results, qualify for conditional marketing authorization from the EMA. For the FDA, centers in the US are required. MEDSIR also has its reaches there. Regulators look at the quality of the data, not the sponsor. Before dreaming of further steps, the work must first begin, starting with the dose finding; that phase can probably be conducted in Barcelona alone. We are following the announcements.

Fees for the underwriting commitments have been paid, and due to the pricing of the offering and the share price, the fee is likely quite large.

Faron Pharmaceuticals

On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. 

Translation: Original comment published in Finnish on 7/19/2023 at 6:40 am. On Wednesday, Faron Pharmaceuticals <a href="https://www.inderes.se/releases/faron-pharmaceuticals-oy-bexmab-study-update-4">published</a> new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also stated that they plan to file the first Biologics License Application (BLA) to FDA in H1’25. According to the company, the data received so far in the study supports moving to clinical Phase II. This move is already included in our modeling as a very likely scenario in our estimates. So there is no need for major estimate changes, but we will review our assumptions in connection with our Q2 pre-comment. Our latest update on Faron is available <a href="https://www.inderes.se/research/faron-pharmaceuticals-bexmab-studys-good-momentum-supports-valuation">here.</a>

	2022	23e	24e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-27.4	-15.8	-3.1
EBIT-% (adj.)	-685,650.0 %	-394,522.5 %	-76,864.0 %
EPS (adj.)	-0.46	-0.24	-0.05
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Promising results from Faron's BEXMAB blood cancer study

Key Estimate Figures17.04.2023

Forum discussions